1279P Prevalence of EGFR mutations (EGFRm) in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR LATAMdoi:10.1016/j.annonc.2023.09.757E. AmorinH.A. PerroudL.G-H. HellalS.V. FranciscoA.P. GuerreroA. VasquezL.F.T. GallegosN. DonnerR. HuggenbergerL. CorralesElsevier LtdAnnals of O...
Both point mutations in exon 18 and insertion mutations in exon 20 are relatively infrequent, respectively, at 3% and 5% of theEGFRmutations14,15. With more than 1.6 million cases of lung cancer diagnosed and 1.3 million deaths per year16, even small subgroups of NSCLC contribute to significant...
Current and emerging actionable alterations in non-squamous NSCLC can be broadly classified as point mutations, insertions/deletions, and amplifications (e.g., EGFR, BRAF, KRAS G12C, MET, and ERBB2/HER2), or gene rearrangements (e.g., ALK, ROS1, RET, and NTRK1-3) [2]. Clinical ...
Molecular characterization of cancers with NTRK gene fusions. Mod. Pathol. 32, 147–153 (2019). Article CAS PubMed Google Scholar Xia, H. et al. Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese...
The reported incidence of HER2 protein over- expression using IHC and gene amplification is 2.4–38% and 10–20%, respectively [16–20]. HER2 mutations in NSCLC were first reported in 2004, with an incidence of up to 4% [21]. Unlike breast cancer, the molecular asso- ciations between ...
Little is known about prevalence of PD-L1 expression in tumor cells of unselected patients with all stages of non-small cell lung cancer. The objective of this study is to assess the prevalence of PD-L1 positivity in patients with non-small cell lung can
Drug resistance represents a major obstacle in cancer management, and the mechanisms underlying stress adaptation of cancer cells in response to therapy-induced hostile environment are largely unknown. As the central organelle for cellular energy supply,
The presence of actionable mutations in the epidermal growth factor receptor (EGFR) gene is a key predictor of how a patient will respond to a TKI. Thus, the frequency of identification of mutations in EGFR gene in patients with NSCLC can facilitate personalized treatment. Objective: The ...
reporting the prevalence of rare/uncommon EGFR gene mutations in nonsmall-cell lung cancer (NSCLC), in a retrospective cohort of 3856 Polish Caucasian patients [1]. As in France, a lot of platforms for molecular analysis of cancers have developed alternative molecular targeted analyses to ...
(2015) Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiology 39 , 291-297 /...